RxDoctor Payments Data

Tushina Reddy, MD

Ophthalmology · Las Vegas, NVNPI 1154410801

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 37.6% of the total.

$11,091in general payments, 2019–2025

Across 98 payments — averaging $113.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$4K
  • Rxsight Inc$1K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Aerie Pharmaceuticals, Inc.$919
  • Alcon$903
  • AbbVie$411
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$6005%
  • Speaking & faculty fees$260%
  • Travel & lodging$3,91735%
  • Food & beverage$6,54859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,091 in reported general payments places this provider in the 85th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$276,731
Medicare patients
868
Services billed
2,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine77$61,943
XdemvyLotilaner13$24,717
LumiganBimatoprost22$14,649
Cyclosporine43$14,393
RocklatanNetarsudil Mesylat/Latanoprost13$9,957
Latanoprost651$6,059
Prednisolone Acetate82$4,399
Timolol Maleate154$1,277
Brimonidine Tartrate54$834
Ketorolac Tromethamine19$771
ErythromycinErythromycin Base75$727
Ofloxacin47$688
Dorzolamide Hcl31$540
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat50$513
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha29$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$411$76,59299 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$364$24,71713 claims
Aerie Pharmaceuticals, Inc.Rocklatan$919$9,95713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 121 ophthalmology providers in Nevada.

Other ophthalmology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →